Pfizer wins EU permission to buy Hospira for US$15 billion
The European Union gave Pfizer the green light on Tuesday to purchase rival Hospira for US$15 billion.
This is provided that Pfizer sell some drugs to ward off competition concerns.
“The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development,” the European Commission said.
The deal will boost Pfizer’s portfolio of generic injectable drugs and copies of biotech medicines
Category: Features, Pharmaceuticals
